Navigation Links
Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
Date:6/19/2009

dification or additional methods may need to be developed, the success of which is not assured, due to possible future changes in the L-DOS47 formulation or manufacturing process, requirements of regulatory authorities, or other factors; the need to further upscale the manufacturing process for the Company's drug candidates and the risk that further upscaling may not be achieved within the timelines expected by the Company or at all; the need for regulatory approvals, which may not be obtained in a timely manner or at all; the need for clinical trials, the occurrence and success of which cannot be assured; intellectual property risks; marketing/manufacturing risks and partnership/strategic alliance risks, including Helix's dependency on KBI Biopharma Inc. and its other contractors, consultants and advisors, whose performance and interdependence can critically affect the Company's performance and the achievement of its milestones; product liability risks; the effect of competition; the risk of technical obsolescence; and the risk of changes in business strategy or development plans. Such risks and uncertainties, and others affecting the Company which could cause actual results to vary materially from current results or those anticipated in forward-looking statements and information, are more fully described in the Company's latest Annual Information Form, MD&A and other reports filed with the Canadian Securities Regulatory Authorities from time to time at www.sedar.com, and in the Company's Form 20-F and other reports filed with the U.S. SEC from time to time (see www.sec.gov/edgar.shtml). Forward-looking statements and information are based on the beliefs, assumptions, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement or information should tho
'/>"/>
SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
2. Helix BioPharma to Present at the BioFinance 2009 Conference
3. Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division
4. Helix BioPharma Announces Q2 2009 Financial Results
5. Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions
6. Helix BioPharma Form 20-F Registration Statement Declared Effective by SEC
7. London-Based Double Helix Consulting Launches US Division for Strategic Pricing, Reimbursement and Market Access Solutions
8. Helix BioPharma Announces Q1 2009 Financial Results
9. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
10. Helix BioPharma Corp. Announces Fiscal 2008 Results
11. Helix Biopharma Closes $11.4 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , September 2, 2015 BiondVax Pharmaceuticals ... the National Institute of Allergy and Infectious Diseases (NIAID), part ... Department of Health and Human Services (HHS), to launch a ... the United States in the 2015-16 timeframe. The ... candidate, Multimeric-001 (M-001), as a primer vaccine, which would be ...
(Date:9/2/2015)... ... September 02, 2015 , ... Whitehouse Laboratories is excited ... Pharma Ed Resources upcoming educational seminar and training session on Extractable & Leachable ... conference will provide Updates & Case Studies on the Latest Compliance Implications of ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... science research, today unveiled Genedata Screener ® version 13.0 at ELRIG Drug ... brings to market a rich set of new capabilities. Screener now supports High ...
(Date:9/1/2015)... , Sept. 1, 2015 The American ... Intent (LOI) for its Discovery Research Grant program. LOIs ... at 12:00 noon CDT. Discovery Grants ... with the potential to change current diagnostic or treatment ... grants specifically encourage novel research at its earliest stages, ...
Breaking Biology Technology:BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 2BiondVax Announces Intent to Launch a Phase 2 Trial in the United States in Collaboration with the U.S. National Institutes of Health 3Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 2Whitehouse Laboratories to Participate in Pharm Ed Resources Extractables, Leachables, & Elemental Impurities Educational Seminar 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4American Brain Tumor Association Seeks Innovative Concepts For Discovery Research Grants 2
... Lentigen Corporation announced today,that it has received ... research (SBIR) grants to collaborate with leading,scientists. Through ... (LV) technology to the development of novel,immunotherapeutic treatments ... -- Melanoma, with Michael Nishimura, Ph.D, Associate ...
... 15 Baxa Corporation, a,Denver-based manufacturer of medical ... Marketing Association Gold Key Awards for its,integrated direct ... Colorado,s most highly acclaimed marketing competitions, the BMA,Gold ... on May 3rd at the,Cable Center at the ...
... a leading life sciences company, announced today that the ... Executive Officer,and a member of the Cambrex Corporation Board ... and Chief Executive Officer since 1995,and Chairman since 1999, ... the positions of Board Chairman and CEO and John ...
Cached Biology Technology:Lentigen Corporation Receives Four Research Grants From the National Institutes of Health 2Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards 2Baxa Corporation Wins Two Colorado BMA 2008 Gold Key Awards 3Cambrex Appoints Steven M. Klosk as President and CEO 2
(Date:8/6/2015)... Calif. , Aug. 6, 2015 ... developer of human interface solutions, today announced collaboration ... technologies on Windows 10. Microsoft leveraged Synaptics, deep ... the operating system. Through stringent ... are fully certified with Microsoft,s Precision TouchPad (PTP) ...
(Date:8/5/2015)... August 5, 2015 Transparency Market ... Recognition Market - Global Industry Analysis, Size, Share, Growth, ... for facial recognition is forecast to reach US$ 2,671.8 ... demand for surveillance systems by civil and government agencies. ... crimes and terrorist activities across the globe that would ...
(Date:8/4/2015)... 04, 2015 ... announced the addition of the "Digital ... Service), Sub-Segment (Computer Forensics, Network Forensics, Mobile ... Service, Vertical and Region - Global Forecast ... By Component (Hardware, Software, and ...
Breaking Biology News(10 mins):Synaptics Chosen for Human Interface Co-Development on Windows 10 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2
... retailer of wine products, BRSM Sales LLC, today announced the ... holiday shopping: www.GreatWineProducts.com . The new ... products including but not limited to: glass and stemware, burlap ... In addition to personal use, many items make ...
... the fight against pneumonia is the focus of ... University ePress., With an aim to establish an ... ,is a peer-reviewed, open-access journal which brings together ... Griffith,s Professor Allan Cripps is the Editor in ...
... 2013 New data suggest that the transcription ... Researchers determined that alcohol given to mice deficient ... alcoholic hepatitis. Further they found that although hepatitis ... in combination they suppressed FOXO3, reduced expression of ...
Cached Biology News:Griffith joins the fight against pneumonia 2Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol 2Transcription factor may protect against hepatic injury caused by hepatitis C and alcohol 3
... uptake of long double stranded RNA (dsRNA) ... in a diverse group of organisms as ... interference leads to the inhibition of protein ... the target messenger RNA (mRNA). Attempts to ...
... Powerful exact mass measurements in ... orthogonal electrospray time-of-flight mass spectrometer (ESI-oa-TOF) ... machine in a format, which fits ... a mass resolution exceeding 10,000 FWHM ...
... Performance The TSQ Quantum Ultra defines ... bioanalytical and environmental analysis. It features ... APCI probes, a titanium skimmer with superior ... and sensitivity. Its redesigned ion transfer ...
... of long double stranded RNA (dsRNA) has ... a diverse group of organisms as well ... leads to the inhibition of protein expression ... target messenger RNA (mRNA). Attempts to induce ...
Biology Products: